Trending Now
What’s the Next Big Thing in the Oil Space? (SBOW, PQEFF,...
The energy space is the unambiguous market leading group so far in 2022. And there’s plenty of data out there to suggest...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
vTv Therapeutics Inc. (NASDAQ:VTVT) Announces Its Q3 2020 Financial Results And...
vTv Therapeutics Inc. (NASDAQ:VTVT) has announced its Q3 financial results and provided updates on its clinical programs.
vTv completed enrolment in Elavage study of azeligaron...
MAKE IT MODERN
LATEST REVIEWS
Verona Pharma PLC (VRNA) Hits All-Time High Amid COPD Treatment Breakthrough...
Verona Pharma PLC (NASDAQ: VRNA), a trailblazer in respiratory disease treatments, is currently riding a wave of success, having reached an all-time...
MAKE IT MODERN
PERFORMANCE TRAINING
Could it be Time for Watch Stocks? (MOV, FOSL, CLKA, TIF)
The pandemic has decimated certain market segments. And much of this destruction may be overdone, especially given rapid progress on vaccine and monoclonal antibody...
Invesco QQQ Trust (QQQ) is on the recovery rally mode
Invesco QQQ Trust (QQQ) last traded at $280.97+1.92 (+0.69%). QQQ traded in the range of $276.17 - $281.21 with more than 44,802,936 shares...
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Begins Phase 2 Clinical Study of Vixarelimab in Prurigo Nodularis
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) commenced a phase 2 clinical study of the drug – Vixarelimab with the first dosing in prurigo nodularis....
iTeos Therapeutics (NASDAQ: ITOS) Sees Surge in Stock and Advances in Oncology Treatments and...
iTeos Therapeutics, Inc. (NASDAQ: ITOS), a trailblazer in the field of immuno-oncology, is witnessing significant strides both in the market and within...
Orchard Therapeutics (NASDAQ:ORTX) Granted PRIME Designation For OTL-203 In Treating MPS-1
Orchard Therapeutics (NASDAQ:ORTX) has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for its experimental ex vivo autologous hematopoietic stem cell...
MAKE IT MODERN
